Liquidia is a biopharmaceutical company focused on rare cardiopulmonary diseases, notably pulmonary arterial hypertension and related conditions. Its lead commercial product, YUTREPIA (treprostinil) inhalation powder, is designed for inhaled delivery of prostacyclin therapy. The company builds on proprietary PRINT particle-engineering technology to shape drug particles for more precise pulmonary delivery.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 8.8 | — | -41.6 | — |
| Q3 2025 | 54.3 | — | -3.5 | — |
| Q4 2025 | 92 | — | 14.6 | — |
| Q1 2026 | 132.9 | — | 52.9 | — |
| Q2 2026 | 171.7 | 1,842.7% | 74.7 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: SPS Commerce, Inc. (SPSC), NMI Holdings, Inc. (NMIH), Pattern Group Inc. (PTRN), United States Lime & Minerals, Inc. (USLM), First Hawaiian, Inc. (FHB), AvePoint, Inc. (AVPT)